Course Faculty, IAS–USA Staff, and Board of Directors

Financial Relationships With Ineligible Companies

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with ineligible companies (formerly commercial interests) within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as "those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients." Below are the financial interests that faculty members of this course have had within the past 24 months as of the date listed. View the Faculty Financial Disclosure Policy.

Hot Topics in HIV Medicine: A Special IAS-USA CME Course – February 5, 2021

Course Presenters	
Susan Buchbinder, MD Clinical Professor, Medicine and Epidemiology University of California San Francisco San Francisco, California	Dr Buchbinder has no relevant financial relationships with ineligible companies to disclose. (Updated 01/21/2021)
Eric S. Daar, MD Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Los Angeles, California	Dr Daar has received research support awarded to his institution from Gilead Sciences, Inc., Merck & Co, Inc., and ViiV Healthcare. He also received consultant or advisor fees from Gilead Sciences, Inc., Merck & Co, Inc., ViiV Healthcare, and Genentech. (Updated 02/01/21)
Carlos del Rio, MD Distinguished Professor of Medicine Emory University Atlanta, Georgia	Dr del Rio has no relevant financial affiliations with ineligible companies to disclose. (Updated 06/20/20)
Kristine M. Erlandson, MD, MS Associate Professor of Medicine and Epidemiology University of Colorado Denver Denver, Colorado	Dr Erlandson has received grants paid to her institution from Gilead Sciences, Inc., and served as a consultant to Gilead Sciences, Inc, and ViiV Healthcare. (Updated 01/19/21)
Avindra Nath, MD Chief, Section of Infections of the Nervous System National Institute of Neurological Diseases and Stroke National Institutes of Health Bethesda, Maryland	Dr Nath has no relevant financial relationships with ineligible companies to disclose. (Updated 02/01/21)
Edgar Turner Overton, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama	Dr Overton has served as a consultant for ViiV Tibotec, and Merck Pharmaceuticals. (Updated 01/30/21)

IAS–USA CME Planners and Reviewers	
Susan Buchbinder, MD	Dr Buchbinder has no relevant financial relationships with ineligible companies to disclose. (Updated 01/21/2021)
Carlos del Rio, MD	Dr del Rio has no relevant financial affiliations with ineligible companies to disclose. (Updated 06/20/20)
Avindra Nath, MD	Dr Nath has no relevant financial relationships with ineligible companies to disclose. (Updated 02/01/21)
Paul A. Volberding, MD Professor of Medicine Co-Director, Center for AIDS Research Director, AIDS Research Institute University of California San Francisco San Francisco, California	Dr Volberding has served on data and safety monitoring boards for Merck & Co, Inc. (Updated 06/20/20)
Donna M. Jacobsen Executive Director/President IAS–USA	Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 02/03/21)

IAS–USA Board of Directors

*The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see https://iasusa.org/about/ias-usa-board-of-directors/ for information about board members and a link to up-to-date financial disclosure information.